W W Grainger Inc vs Medtronic PLC — how do they compare? W W Grainger Inc trades at $1,289.79 (market cap $59.76B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and Medtronic PLC for 63 Days on average.
| GWW | MDT | |
|---|---|---|
Market Cap | $59.76B | $112.24B |
Volume | 186,697 | 105,663,236 |
Sector | Industrials | Health |
52-Week High | $1.40K | $105.35 |
52-Week Low | $918.18 | $73.75 |
Typical Hold Time | 25 Days | 63 Days |
Enterprise Value | $61.96B | $131.58B |
Dividend Yield | 0.79% | 3.28% |
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,268.67, up 0.41% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong profitability with 47.92% ROE and 9.92% net margin, though valuation metrics appear elevated with a P/E of 32.34. Recent earnings show two consecutive beats, while analyst consensus leans heavily toward Hold (66.66%) with a $1,310 price target. The company continues strategic expansion with a new Oregon distribution center and technology acquisitions.
GWW presents a balanced outlook with solid fundamentals offset by premium valuation. The stock offers steady dividend growth as a Dividend King but faces headwinds from industrial sector challenges. Upside potential exists if earnings momentum continues, though current levels suggest limited near-term catalysts given the cautious analyst stance and technical resistance near $1,280-$1,303.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong analyst support (60.8% buy ratings) and a $97.80 consensus price target suggesting 11.5% upside. The stock shows consistent earnings beats in recent quarters and maintains a 49-year dividend growth streak. However, technical indicators signal bearish momentum with resistance near $89-90. Revenue growth accelerated to $33.54B in 2025 with net margins improving to 13.93%, though debt levels have risen to 31.1% of assets.
MDT presents a compelling value opportunity with attractive dividend yield and earnings momentum, but faces near-term technical headwinds and increasing leverage. The upcoming Q3 earnings report and MiniMed separation will be critical catalysts. Investors should weigh the strong fundamental recovery against bearish technical signals and monitor debt management closely.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →